A Molecular Docking Study against COVID-19 Protease with a Pomegranate Phyto-Constituents 'Urolithin' and Other Repurposing Drugs: From a Supplement to Ailment
Loading...
Date
2020-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
SCIENCEDOMAIN international
Abstract
Aim:We conducted an in silico study on Urolithin and different antimicrobial agents targeting virus protease and peptidase.Methodology: The dockingstudy was completed by using docking tools. Drug compounds and COVID-19 receptor molecules were prepared, docking was performed and interaction was visualized through Discovery Studio visualizer.Results: Urolithin A has interacted against peptidase (PDBID:2GTB) with binding energy -6.93kcal/mol and against protease (PDBID:6LU7) with the binding energy -5.46 kcal/mol,while Urolithin Bhasinteracted to peptidase (PDBID:2GTB) with binding energy -6.74kcal/moland with protease it interacted with a binding energy -4.67 kcal/mol. The antimicrobial agent Ofloxacin was found to interactagainst protease(PDBID:6LU7) with a binding energy -6.84 kcal/mol and against protease(PDB:6LU7) with a binding energy -8.00 kcal/mol. Conclusion: The most common interacting amino acids of target enzymes of the virus with studied drugs were His41, His164, Met165, Glu166, Gln189. From the docking studies, it is observed that Ofloxacin and Urolithin have the potential to inhibit the virus protease as well as peptidase significantly and these could prevent the entry of the virus to the inside of the host cell. Thus, further antiviral research on these antimicrobial agents and Urolithin could be helpful to control the COVID-19 disease
Description
Keywords
Antimicrobial agents, urolithin, antiviral, SARS-CoV-2, protease
Citation
Ahmadm Varish. A Molecular Docking Study against COVID-19 Protease with a Pomegranate Phyto-Constituents 'Urolithin' and Other Repurposing Drugs: From a Supplement to Ailment. Journal of Pharmaceutical Research International. 2020 Jul; 32(11): 51-62